Russian Heart Failure Journal 2013year Role of evaluation of adrenoreactivity and beta2-adrenoreceptor polymorphism in the development of myocardial remodeling in patients with chronic heart failure

To access this material please log in or register

Register Authorize

Role of evaluation of adrenoreactivity and beta2-adrenoreceptor polymorphism in the development of myocardial remodeling in patients with chronic heart failure

Khazova E. V., Bulashova O. V., Oslopov V. N., Kravtsova O. A.

Keywords: gene polymorphism, myocardial remodeling, CHF

DOI: 10.18087/rhfj.2013.1.1780

Relevance. Now there is no doubt that polymorphism of multiple modifier genes can considerable influence phenotypic manifestations of CVD, including CHF. Considering hypersympathicotonia typical for HF patients, it is important to study functional status of beta-adrenoreceptors. Objective. Study of association of polymorphic markers beta-adrenoreceptors type 2 (ADRB2) with phenotypic manifestations and functional peculiarities of LV myocardium in CHF patients and diverse beta-adrenoactivity of organism. Materials and methods. 132 patients with CHF were examined (46.2 % male and 53.8 % female). FC distribution: I – 3 %, II – 46 %, III – 45 %, IV – 6 %. In all patients, beta-adrenoactivity of organism was assessed, PCR genetic typing was carried out by Arg16Gln and Gln27Glu and ADRB2 gene polymorphic markers. Myocardial structure was studied by EchoCG. Results. Differences in the geometrical models of LV myocardial remodeling was revealed: in patients with normal beta-ARM levels, concentric type prevailed (70 %), in patients with reduced beta-ARM levels – excentric LV hypertrophy (79 %). Genotype study showed higher prevalence of Arg allele in 16 in polymorphic locus in CHF patients. In comparison with the reference group: Arg / Arg (42 and 18 %), Arg / Gln (49 and 38 %) and Glu27Glu (30 and 10.7 %), Glu27Gln (54.5 and 46.9 %). Gln16Gln and Gln27Gln genotypes were rarer, than in the reference group (9 and 44 %) and (15.5 and 42.4 %). Correlation analysis revealed positive interrelation between beta-ARM and SHOKS (r=0.37, р<0.05), LVEF (r=0.28, р<0.05) and RV dimensions (r=0.20, р<0.05), negative correlation with 6 minute walk test results (r= –0.43, р<0.05). Conclusion. Decrease of beta-adrenoactivity is more typical for patients with sever CHF due to CHD, often with postinfarction cardiosclerosis. In CHF patients with decreased beta-adrenoactivity, mainly excentric type of left ventricular hypertrophy is observed. In the group of patients with normal beta-ARM levels, concentric LV remodeling prevails. Decrease of beta-adrenoactivity is revealed in 55 % of patients with Аrg16Gly genotype and in all patients with Gln / Gln genotype, which may reflect protective desensitization of cell membrane in patients of this group. Glu27Glu genotype frequency rate is higher in the group of patients with decreased beta-ARM levels at comparison with the group with normal beta-ARM levels and reference group.
  1. Шляхто Е. В., Конради А. О. Роль генетических факторов в ремоделировании сердечно-сосудистой системы при гипертонической болезни. Артериальная гипертензия. 2003;8 (3):107–113.
  2. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphisms in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol. 2000;20 (2):484–492.
  3. Motawi T, Shaker O, Taha M, Sedrak H, Nabil M. Endothelial nitric oxide synthase and angiotensinogen gene polymorphism in coronary artery diseases in Egypt. Angiology. 2011;62 (2):191–197.
  4. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73 (3):411–418.
  5. Оганов Р. Г. Профилактика сердечно-сосудистых заболеваний в России: успехи, неудачи, перспективы. Тер. архив. 2004;76 (6):22–24.
  6. Koch WJ. Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Mol Cell Biochem. 2004;263 (1-2):5–9.
  7. Post WS, Larson MG, Myers RH et al. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension. 1997;30 (5):1025–1028.
  8. Pelliccia A, Thompson PD. The genetics of left ventricular remo­deling in competitive athletes. J Cardiovasc Med (Hagerstown). 2006;7 (4):267–270.
  9. Almazov VA, Shlyakhto EV, Shwartz E et al. Lack of assotiation of the RAS gene polymorphism and left ventricular hypertrophy. Euro J Heart Failure. 2000;2 (2):11.
  10. Шилов С. Н. Хроническая сердечная недостаточность при ишемической болезни сердца: клинико-генетические механизмы развития и возможности улучшения ранней диагностики, профилактики и медикаментозной терапии. – Автореф. дисс. докт. мед. наук. Томск, 2011. – 50с.
  11. Минушкина Л. О, Никитин А. Г, Затейщиков Д. А. Гипертро­фия миокарда у больных гипертонической болезнью: роль генетического полиморфизма β-адренореактивных структур. Кардио­логия. 2010;50 (1):9–14.
  12. Dishy V, Sofowora GG, Xie HG et al. The effect of common polymorphisms of the beta-2‑adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001;345 (14):1030–1035.
  13. Busiahn A, Li GH, Faulhaber HD et al. Beta-2‑adrenegic receptor gene variations, blood pressure and heart size in normal twins. Hypertension. 2000;35 (2):555–560.
  14. Wagoner LE, Craft LL, Singh B et al. Polymorphisms of the β2‑adre­nergic receptor determine exercise capacity in patients with heart failure. Circ Res. 2000;86 (8):834–840.
  15. Liggett SB, Wagoner LE, Craft LL et al. The Ile164 β2‑adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102 (8):1534–1539.
  16. Covolo L, Gelatti U, Metra M et al. Role of β 1 – and β 2‑adrenoceptor polymorphisms in heart failure a case-control study. Eur Heart J. 2004;25 (17):1534–1541.
  17. Forleo C, Resta N, Sorrentino S et al. Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med. 2004;117 (7):451–458.
  18. Sotoodehnia N, Siscovick DS, Vatta M et al. Beta2‑adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006;113 (15):1842–1848.
  19. Kaye DM, Smirk B, Williams C et al. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003;13 (7):379–382.
  20. Wallerstedt SM, Eriksson A-L, Ohlsson C. et al: Haplotype association analysis of the polymorphisms Argl6Gly and Gln27Glu of the adren ergic 2 receptor in a Swedish hypertensive population. J Hum Hyper tens 2005;19:705–708.
  21. Heckbert SR, Hindorff LA, Edwards KL et al. Beta2‑adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation. 2003;107 (15):2021–2024.
  22. Snieder H, Dong Y, Barbeau P et al. Beta2‑adrenergic receptor gene and resting hemodynamics in European and African American youth. Am J Hypertens. 2002;15 (11):973–979.
  23. Iaccarino G, Lanni F, Cipolletta E et al. The Glu27 allele of the beta 2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J Hypertens. 2004;22 (11):2117–2122.
  24. Минушкина Л. О., Горшкова Е. С., Бровкин А. Н. и др. Ассоци­ация генов бета-адренорецепторов, коннексина-40 и калиевого канала kcnh2 с гипертрофией миокарда левого желудочка у больных гипертонической болезнью. Журнал «Кремлевская медицина. Клинический вестник». 2010;2:26–30.
  25. Базян А. С. Физиологическая роль аутоадренорецепторов. – М.: Наука, 1991. – 159с.
  26. Красникова Т. Л. Бета-2‑адренорецепторная система лимфоцитов человека при некоторых сердечно-сосудистых заболеваниях и действии лекарственных препаратов Автореф. дис. … д-ра биол.наук. – М.: 1993. – 59 с.
  27. Bristow MR, Ginsburg R, Minobe W et al. Decreased catecho­lamine sensivity and beta-adrenergic receptor density in failure human hearts. N Engl J Med. 1982;307 (4):205–211.
  28. Меерсон Ф. З. Феномен адаптационной стабилизации структур и защита сердца. Кардиол.1990;30 (3):6–12.
  29. Antezana AM, Kacimi R, Le Trong JL et al. Adrenergic status of human during prolonged exposure to the altitude of 6,542 m. J Appl Physiol. 1994;76 (3):1055–1059.
  30. González O, González E, Sánchez C et al. Effect of exercise on erythrocyte beta-adrenergic receptors and plasma concentrations of catecholamines and thyroid hormones in Thoroughbred horses. Equine Vet J. 1998;30 (1):72–78.
  31. Bohm M, Gierschiu P, Knorr et al. Desensitisation of adenilatecyclase and increase of G in cardiac hypertrophy due to acquired hypertension. Hypertension. 1992:20 (1);103–112.
  32. Терентьев В. П, Белова Е. В, Зонис Б. Я. Особенности функционирования симпато-адреналовой системы у больны артериальной гипертонией с различными вариантами ремоделирования левого желудочка при его гипертрофии. Росс.кардиол. журн. 2001:5 (4);39–42.
  33. Стрюк Р. И., Длусская И. Г. Адренореактивность и сердечно-сосудистая система. – М.: Медицина, 2003. – 157.
  34. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  35. Chobanian AN, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289 (19):2560–2572.
  36. Линник С. А, Наурбиева Е. Н, Пономарева Е. П. Влияние ингибитора ангиотензинпревращающего фермента периндоприла на вариабельность ритма сердца и адренореактивность у больных с ишемической болезнью сердца, сочетанной с язвенной болезнью двенадцатиперстной кишки. Кардиология. 2007;47 (4):41–44.
  37. Москвина Ю. В, Нечаева Г. И. Адренореактивность у пациентов с аритмическим синдромом, ассоциированным с дисплазией соединительной ткани, на фоне приема магния оротата. Кардиология. 2011;51 (3):54–57.
Khazova E. V., Bulashova O. V., Oslopov V. N. et al. Role of evaluation of adrenoreactivity and beta2-adrenoreceptor polymorphism in the development of myocardial remodeling in patients with chronic heart failure. Russian Heart Failure Journal. 2013;14 (1):34-39

To access this material please log in or register

Register Authorize
Ru En